Clinical Trial Update: Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated mangafodipir as an intracellular MRI contrast agent by measuring manganese uptake in patients with heart failure with preserved ejecti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Mangafodipir (Mangafodipir trisodium)

Snippet

Sponsor: IC TARGETS AS | Conditions: Heart Failure With Preserved Ejection Fraction (HFPEF) | Phase 2 | Status: COMPLETED